{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:13:16Z","timestamp":1779923596972,"version":"3.53.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clinthera.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:50:10Z","timestamp":1698987010000},"page":"e12-e22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ledipasvir\/Sofosbuvir in Hepatitis C Virus\u2013Infected Children With Hematological Malignancies: A Pharmacokinetic Study"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1690","authenticated-orcid":false,"given":"Aya M.","family":"AbdelMagid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie M.","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma S.","family":"Ebeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar F.","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal H.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.10.007_bib0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Jefferies","year":"2018","journal-title":"World J Clin cases"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0002","unstructured":"World Health Organization (WHO). Combating hepatitis B and C to reach elimination by 2030: advocacy brief[Internet]. 2016 [cited 2023 Jan 25]. Available from: https:\/\/www.who.int\/publications\/i\/item\/combating-hepatitis-b-and-c-to-reach-elimination-by-2030."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.9745\/GHSP-D-20-00234","article-title":"Egypt\u2019s ambitious strategy to eliminate hepatitis C virus: a case study","volume":"9","author":"Hassanin","year":"2021","journal-title":"Glob Heal Sci Pract"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJGM.S119301","article-title":"Hepatitis C in Egypt\u2014past, present, and future","volume":"10","author":"Elgharably","year":"2017","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/1348-0421.12916","article-title":"Current situation of viral hepatitis in Egypt","volume":"65","author":"Elbahrawy","year":"2021","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0007","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2468-1253(19)30385-1","article-title":"Global prevalence of hepatitis C virus in children in 2018: a modelling study","volume":"5","author":"Schmelzer","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0008","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MPG.0000000000003406","article-title":"Ledipasvir-sofosbuvir in adolescents with chronic hepatitis C and hematological malignancies undergoing chemotherapy","volume":"74","author":"El-Sayed","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/hep.22094","article-title":"Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial","volume":"47","author":"Goodman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/hep.510280534","article-title":"Histopathology of the liver in children with chronic hepatitis C viral infection","volume":"28","author":"Badizadegan","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0011","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir\u2013sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0012","doi-asserted-by":"crossref","first-page":"7880","DOI":"10.3748\/wjg.v19.i44.7880","article-title":"Burden of pediatric hepatitis C","volume":"19","author":"El-Shabrawi","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0013","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2893.2004.00535.x","article-title":"Hepatitis C virus infection in Egyptian children: single centre experience","volume":"11","author":"El-Raziky","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MPG.0b013e318185998f","article-title":"Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes","volume":"48","author":"Rodrigue","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0015","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1440-1746.2007.04859.x","article-title":"Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life","volume":"23","author":"Nydegger","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12032-013-0559-y","article-title":"Treatment for hepatitis C virus\u2013induced portal hypertension in leukemic children","volume":"30","author":"El-Ashry","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2020.08.088","article-title":"Treatment of chronic hepatitis C in young children reduces adverse outcomes and is cost-effective compared with deferring treatment to adulthood","volume":"230","author":"Greenaway","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0018","unstructured":"World Health Organization (WHO). Hepatitis C [Internet]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.10.007_bib0019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"Schinazi","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0020","unstructured":"Food and drug administration (FDA). FDA approves two hepatitis C drugs for pediatric patients [Internet]. [cited 2023 Apr 14]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-two-hepatitis-c-drugs-pediatric-patients."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0021","unstructured":"World Health Organization (WHO). Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection Policy Brief [Internet]. 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240052710."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0022","unstructured":"Gilead Sciences Inc. Reference ID: 4483725. HARVONI\u00ae (ledipasvir and sofosbuvir)tablets, for oral use. US prescribing information. [Internet]. Revised. 2019 Aug [cited 2023 Jan 11]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212477s000lbl.pdf."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0023","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0024","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40262-016-0397-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of ledipasvir\/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C","volume":"55","author":"German","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0025","unstructured":"European Medicines Agency. Assessment report. 2020;31(April). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/harvoni-h-c-3850-x-0081-g-epar-assessment-report-extension_en.pdf."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0026","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood.V93.11.3672.411k04_3672_3677","article-title":"Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease","volume":"93","author":"Paul","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0027","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jiac.2015.05.011","article-title":"Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia","volume":"21","author":"Mattiuzzi","year":"2015","journal-title":"J Infect Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.10.007_bib0028","first-page":"77","article-title":"Methotrexate absorption in children with acute lymphoblastic leukemia","volume":"65","author":"Craft","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijantimicag.2014.09.006","article-title":"First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients","volume":"45","author":"Blackburn","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF03261928","article-title":"Fundamentals of population pharmacokinetic modelling","volume":"51","author":"Kiang","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0031","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/jcpt.13801","article-title":"Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics","volume":"47","author":"Wu","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0032","unstructured":"Pharmacokinetics of Ledipasvir\/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy\u2014Full Text View\u2014ClinicalTrials.gov [Internet]. [cited 2023 Apr 14]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03903185."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0033","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki:\u202fEthical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0034","series-title":"Davis's Comprehensive Manual of Laboratory and Diagnostic Test with Nursing Implications","first-page":"81","author":"Van Leeuwen","year":"2019"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0035","unstructured":"Zheng J, Florian J, Seo S. Office of Clinical Pharmacology Review [Internet]. Vol. 205834 (S_. 2015. Available from: https:\/\/www.fda.gov\/media\/104728\/download."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0036","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0091270011422812","article-title":"Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies","volume":"52","author":"Wang","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0037","unstructured":"Food and drug administration (FDA). General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products [Internet]. [cited 2023 Apr 14]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.10.007_bib0038","first-page":"S124","article-title":"Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia","volume":"83","author":"Pui","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113251","article-title":"Adverse event burden score\u2014a versatile summary measure for cancer clinical trials","volume":"12","author":"Le-Rademacher","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0040","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. 2017 [cited 2023 Feb 23]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0041","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0042","unstructured":"Food and drug administration (FDA). Bioanalytical Method Validation Guidance for Industry [Internet]. [cited 2023 Apr 14]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4155\/bio.13.298","article-title":"New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR","volume":"6","author":"Zimmer","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0044","unstructured":"Food and drug administration (FDA). Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application [Internet]. [cited 2023 Apr 14]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0045","unstructured":"PKanalix user guide. NCA Settings [Internet]. 2023. Available from: https:\/\/pkanalix.lixoft.com\/nca-settings\/."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0046","unstructured":"Zheng JH, Chinn L, Reviewer Shirley Seo SK, Florian J, Wang Y. Office of Clinical Pharmacology Review [Internet]. 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205834Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0047","first-page":"743","article-title":"Application of confidence intervals to bioanalytical method validation\u2014drug stability in biological matrix testing","volume":"65","author":"Rudzki","year":"2008","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0048","unstructured":"Food and drug administration (FDA). Reference ID: 4069037. Clinical and Cross-Discipline Team Leader Review (Harvoni) [Internet]. 2017. Available from: www.fda.gov\/media\/104723\/download."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0049","unstructured":"Gilead Sciences Inc. Reference ID: 3719465. HARVONI\u00ae (ledipasvir and sofosbuvir)tablets, for oral use. US prescribing information. [Internet]. Revised . 2015 Mar [cited 2023 Jan 10]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205834s001lbl.pdf."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0050","unstructured":"Centers for Disease Control and Prevention (CDC). Growth Charts\u2013Data Table of BMI-for-age Charts [Internet]. [cited 2023 Apr 14]. Available from: https:\/\/www.cdc.gov\/growthcharts\/html_charts\/bmiagerev.htm."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0051","first-page":"1085","article-title":"Surface area in children: a simple formula","volume":"46","author":"Furqan","year":"2009","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0052","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0053","unstructured":"Drugs.com.Drug Interaction Checker [Internet]. [cited 2023 Sep 16]. Available from: https:\/\/www.drugs.com\/drug_interactions.html."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0040-1708812","article-title":"Hepatitis C virus treatment in children: a challenge for hepatitis C virus elimination","volume":"40","author":"El-Sayed","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0056","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","article-title":"HCV transmission in industrialized countries and resource-constrained areas","volume":"11","author":"Thursz","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0057","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JOP.19.00370","article-title":"Oncologic implications of chronic hepatitis C virus infection","volume":"15","author":"Hwang","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0058","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2016-05-718643","article-title":"How I treat hepatitis C virus infection in patients with hematologic malignancies","volume":"128","author":"Torres","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0059","first-page":"411","article-title":"The oncologic burden of hepatitis C virus infection: a clinical perspective","volume":"67","author":"Torres","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0060","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0061","unstructured":"American Association for the Study of Liver Diseases. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C [Internet]. [cited 2023 May 26]. Available from: https:\/\/www.hcvguidelines.org\/."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0062","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jfma.2022.01.012","article-title":"Ledipasvir\/sofosbuvir for HCV genotype 1, 2, 4\u20136 infection: real-world evidence from a nationwide registry in Taiwan","volume":"121","author":"Lo","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0063","unstructured":"American Society of Hematology. Leukemia [Internet]. [cited 2023 May 25]. Available from: https:\/\/www.hematology.org\/education\/patients\/blood-cancers\/leukemia."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0064","unstructured":"American Association for the Study of Liver Diseases. HCV Guidance: HCV in Children [Internet]. [cited 2023 May 26]. Available from: https:\/\/www.hcvguidelines.org\/unique-populations\/children."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0065","unstructured":"The Association for Clinical Biochemistry and Laboratory Medicine. AFP Tumour Marker [Internet]. [cited 2023 May 25]. Available from: https:\/\/labtestsonline.org.uk\/tests\/afp-tumour-marker-test."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0066","series-title":"Use of the Child Pugh Score in Liver Disease. In: StatPearls [Internet]","author":"Tsoris","year":"2023"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0067","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1148\/radiology.144.4.7111740","article-title":"Sonography of the normal pediatric gallbladder and biliary tract","volume":"144","author":"McGahan","year":"1982","journal-title":"Radiology"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0068","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.jpedsurg.2012.11.047","article-title":"Ultrasonographic dimensions of the common bile duct in Chinese children: results of 343 cases","volume":"48","author":"Zhang","year":"2013","journal-title":"J Pediatr Surg"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2023.10.007_bib0069","first-page":"1269","article-title":"Pharmacokinetics profile of serum and cellular sofosbuvir along with its concentration effect analysis in HCV patients receiving sofosbuvir and ribavirin","volume":"32","author":"Ahmed","year":"2019","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/j.ackd.2017.09.011","article-title":"Measurement and estimation of glomerular filtration rate in children","volume":"24","author":"Mian","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0071","first-page":"15","article-title":"Factors influencing the intracellular concentrations of the sofosbuvir metabolite GS-331007 (in PBMCs) at 30 days of therapy","author":"Cusato","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0072","unstructured":"Jin F, Kirby B, Gao K, Mathias A. Population Pharmacokinetic Modeling of Sofosbuvir, an NS5B Polymerase Inhibitor, and Its Metabolites in Patients With Hepatitis C Virus Infection [Internet]. 2015 [cited 2023 Sep 10]. Available from: https:\/\/www.page-meeting.org\/pdf_assets\/3129-PAGEposter.pd."},{"key":"10.1016\/j.clinthera.2023.10.007_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101747","article-title":"El-Sayed MH. Beta-thalassemia major alters sofosbuvir\/ledipasvir exposure in hepatitis C virus infected adolescent patients","volume":"45","author":"El-Baraky","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.007_bib0074","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1060028017693348","article-title":"Identification of predictors for treatment failure in hepatitis C virus patients treated with ledipasvir and sofosbuvir","volume":"51","author":"Jansen","year":"2017","journal-title":"Ann Pharmacother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:00Z","timestamp":1758963600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823003995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0149291823003995"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.10.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ledipasvir\/Sofosbuvir in Hepatitis C Virus\u2013Infected Children With Hematological Malignancies: A Pharmacokinetic Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}